Personal Capital Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Personal Capital Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$17.6K	Buy	+942	New	+$21.4K	﹤0.01%	486

Other funds holding INO

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Personal Capital Advisors's INO Position: Q4 2022 in Review

Personal Capital Advisors opened a new position in Inovio Pharmaceuticals (INO) in Q4 2022: 942 shares worth $17.6K. The stake represents ﹤0.01% of the portfolio and ranks #486 among its holdings.

182 funds tracked by Wall St. Rank hold INO as of Q4 2022.

Personal Capital Advisors held 942 shares of Inovio Pharmaceuticals worth $17.6K as of Q4 2022.
Inovio Pharmaceuticals was a new Personal Capital Advisors position in Q4 2022.
Inovio Pharmaceuticals made up ﹤0.01% of Personal Capital Advisors's portfolio in Q4 2022, its #486 holding.
182 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.